Sasanlimab drug page Clinical trials

Trials with Sasanlimab

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

6Trials
0Recruiting
6Countries
127Planned patients

Showing 1–6 of 6

A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Finished Phase 1 4 patients NCT06580938

The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07921585) in people with cancer that has advanced or spread to other parts of the body. This study is seeking participants who have any of…

United States Nov 2024 – Jul 2025 Interventional
Combined with: PF-07921585
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Finished Phase 1 9 patients NCT06546553

The purpose of this study is to learn about the: * safety (the effect of the study medicine on the participant's body), * effects of the study medicine alone or in combination with sasanlimab - * the best amount of the study medicine. Th…

United States Sept 2024 – Oct 2025 Interventional
Combined with: PF-07826390
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
Finished Phase 1 4 patients NCT06448364

The purpose of this study is to learn about the safety (the impact of the study drug on the participant's body), effects of the study drug alone or in combination with bevacizumab or sasanlimab, and to find the best dose. This study is se…

United States, Puerto Rico May 2024 – Aug 2024 Interventional
Combined with: BevacizumabPF-07329640
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Finished Phase 1 9 patients NCT06285097

This study aims to evaluate the safety, and early signals of anti-tumor activity of PF-07820435 when administered alone (Part 1A) or in combination with sasanlimab (Part 1B; Part 2) in patients with selected advanced or metastatic solid tu…

United States, Japan, Puerto Rico Feb 2024 – Feb 2025 Interventional
Combined with: PF-07820435
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Finished Phase 1 13 patients NCT05061537

This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of PF-07263689, eith…

United States Oct 2021 – Oct 2022 Interventional
Combined with: PF-07263689
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Finished Phase 1 88 patients NCT04458259

A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors

United States, Canada, Italy, Japan and 1 more Sept 2020 – Nov 2024 Interventional
Combined with: AxitinibPF-07265807